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Abstract
Background: The efficacy of combined psychotherapy and benzodiazepine treatment for panic disorder
is still unclear despite its widespread use. The present systematic review aims to examine its efficacy
compared with either monotherapy alone.
Methods: All randomised trials comparing combined psychotherapy and benzodiazepine for panic
disorder with either therapy alone were identified by comprehensive electronic search on the Cochrane
Registers, by checking references of relevant studies and of other reviews, and by contacting experts in
the field. Two reviewers independently checked eligibility of trials, assessed quality of trials and extracted
data from eligible trials using a standardized data extraction form. Our primary outcome was "response"
defined by global judgement. Authors of the original trials were contacted for further unpublished data.
Meta-analyses were undertaken synthesizing data from all relevant trials.
Results: Only two studies, which compared the combination with behaviour (exposure) therapy, met our
eligibility criteria. Both studies had a 16-week intervention. Unpublished data were retrieved for one study.
The relative risk for response for the combination was 1.25 (95%CI: 0.78 to 2.03) during acute phase
treatment, 0.78 (0.45 to 1.35) at the end of treatment, and 0.62 (0.36 to 1.07) at 6–12 months follow-up.
Some secondary outcomes hinted at superiority of the combination during acute phase treatment.
One study was identified comparing the combination to benzodiazepine. The relative risk for response
was 1.57 (0.83 to 2.98), 3.39 (1.03 to 11.21, statistically significant) and 2.31 (0.79 to 6.74) respectively.
The superiority of the combination was observed on secondary outcomes at all the time points. No sub-
group analyses were conducted due to the limited number of included trials.
Conclusion: Unlike some narrative reviews in the literature, our systematic search established the
paucity of high quality evidence for or against the combined psychotherapy plus benzodiazepine therapy
for panic disorder. Based on limited available published and unpublished data, however, the combined
therapy is probably to be recommended over benzodiazepine alone for panic disorder with agoraphobia.
The combination might be superior to behaviour therapy alone during the acute phase, but afterwards this
trend may be reversed. We know little from these trials about their adverse effects.
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Background
Panic disorder is characterized by the repeated occurrence
of unexpected panic attacks, i.e. abrupt strong fears with
anticipation of death, often accompanied by somatic
symptoms such as palpitations, dyspnoea or faintness.
Applying recent diagnostic criteria including DSM-III-R
and DSM-IV, epidemiological studies have reported
annual prevalence at 2.3% [1], 2.2% [2] and 2.7% [3].
One-third to one-half of patients with panic disorder in
community samples is also diagnosed to have agorapho-
bia [4].
Two broad categories of treatment have been shown to be
effective in treating panic disorder; one is pharmacother-
apy including benzodiazepines and antidepressants, and
the other is psychotherapy including behaviour therapy
and cognitive behaviour therapy.
Recent guidelines recommended selective serotonin
reuptake inhibitors (SSRIs) as the first-line pharmacolog-
ical treatment and argued that its efficacy was comparable
to psychotherapy alone [5]. However, the most recently
published systematic review has shown that the combined
antidepressant plus psychotherapy was superior to either
monotherapy in the short term, and also superior to anti-
depressant alone but was as good as psychotherapy alone
in the long term [6].
Benzodiazepines have been the most frequently pre-
scribed medication for patients with panic disorder [7,8].
There are some advantages to treatment with benzodi-
azepines in that they lead to effects on panic attacks earlier
[9] with milder adverse effects than antidepressants [10].
Nevertheless, the use of benzodiazepines has been associ-
ated with sedation, reduced coordination, cognitive
impairments [11], increased accident proneness [12,13]
and development of dependence [14], and it has been
reported that a rebound of panic attacks can occur during
taper [15].
Psychotherapy has also been reported to be effective in
treating panic disorder [16-23] and is a potential alterna-
tive to the use of benzodiazepines without any adverse
drug effects. On the other hand, psychotherapy has been
said to need longer time to show its effects on panic disor-
der than benzodiazepines [9].
A benzodiazepine and psychotherapy are widely used
together in practice. In a specialized clinic for cognitive-
behaviour therapy, over three quarters of the patients were
given benzodiazepines [24]. However, little evidence
exists so far for any additional benefit to combination
therapy and, if so, whether the benefit is worth the extra
cost of combining two treatments [25-27]. Furthermore,
some observational studies suggested that benzodi-
azepines actually interfered with cognitive-behavioral
interventions [28-31], while others [32,33] suggested oth-
erwise. We therefore need stronger evidence to get a more
precise estimate of their efficacy and safety.
The primary objective of the present systematic review is
to comprehensively search for and synthesize the best evi-
dence on the combined psychotherapy plus benzodi-
azepines in comparison with either treatment alone for
panic disorder with or without agoraphobia, in both the
short- and long-term.
Methods
Inclusion criteria
All relevant randomised controlled trials comparing com-
bined benzodiazepine and psychotherapy with either
therapy alone in adult patients with panic disorder with or
without agoraphobia, diagnosed according to operation-
alized criteria such as DSM-III, DSM-III-R, DSM-IV or
ICD-10 were included. Patients with secondary mental
disorders were included but the effect of this decision was
to be examined in a sensitivity analysis.
For psychotherapies, individual or group forms of psycho-
logical treatments, such as cognitive therapy, behaviour
therapy, cognitive-behaviour therapy and psychodynamic
therapy were included regardless of their frequency and
duration.
Our primary outcome both of short-term and long-term
efficacy was "response" defined by global judgement,
such as "very much" or "much" improved in Clinical Glo-
bal Impressions – Improvement scale if the data were
available. When global assessment data were not availa-
ble, reduction from the baseline in phobic avoidance was
used for response. We did not take account of the number
or severity of panic attacks as our definition of response,
because it was not panic but rather phobic avoidance that
has been shown to correlate with the severity of panic dis-
order with agoraphobia [34].
We also examined global severity, frequency or severity of
panic attacks, phobic avoidance, general anxiety, depres-
sion, social functioning, patients' satisfaction and cost
effectiveness.
Adverse effects were evaluated by looking at the number
of dropouts due to adverse effects, and total number of
dropouts for any reason was examined as a proxy measure
of treatment acceptability.
Identification of trials
We electronically searched the Cochrane Collaboration
Depression, Anxiety and Neurosis Group Registers
(CCDAN REGISTERS) on October 11, 2005. This compre-BMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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hensive register is updated regularly adding the results of
searches of The Cochrane Library, MEDLINE (1966-),
EMBASE (1980-), CINAHL (1982-), PsycINFO (1974-),
PSYNDEX (1977-) and LILACS (1982–1999) and hand-
searches of major psychiatric, medical journals, confer-
ence proceedings and trial registers. Moreover, the register
is being coded continuously with respect to characteristics
of studies such as the kind of interventions and their con-
comitant use, by looking through the full article of rele-
vant studies manually. The studies already coded are
being stored in CCDANCTR-Studies and the others in
CCDANCTR-References. The register contains more than
24,000 records on trials comparing treatment options
within the scope of the CCDAN. One complementary
search for additional relevant trials was conducted with
The Cochrane Central Register of Controlled Trials (CEN-
TRAL).
Three independent reviewers (NW, RC and TAF) exam-
ined titles and abstracts of studies identified by the elec-
tronic searches and then checked full articles for
eligibility. To identify further trials, references of these
selected studies and of other review papers were also
checked, representative studies were subjected to Sci-
Search and experts in the field were contacted. No lan-
guage restriction was imposed.
Quality assessment and data extraction
Two independent reviewers (NW and TAF) assessed the
methodological quality of the selected studies.
The criteria for quality assessment were based on recom-
mendations in the Cochrane Handbook for Systematic
Reviews of Interventions [35], which focused on the qual-
ity of allocation concealment. We also rated whether at
least one outcome measure was assessed by an independ-
ent assessor blind to treatment allocation. In addition,
regarding psychotherapy, its adequacy is considered to be
essential for effective treatment, and to depend on the
expertise of the practitioner and the therapist's adherence
to a particular form of therapy. We assessed the adequacy
of psychotherapy in each study and if the authors gave suf-
ficiently detailed description of the therapy procedure,
and if audiotapes of the psychotherapy process were
examined by a third reviewer. The three reviewers inde-
pendently extracted data from the original reports using
data extraction forms. For studies where exact numbers of
responders were not presented but only their means and
standard deviations (SDs) of the global severity measure,
we imputed response rates by using a validated imputa-
tion method [36] in order to conduct intention-to-treat
(ITT) analyses as described below. Any disagreement was
resolved by consensus between all three reviewers.
Data synthesis
Data were double-entered into Review Manager 4.2 to
check for accuracy. Meta-analyses were then performed.
For dichotomous outcomes, ITT analysis was adopted.
When dropouts were excluded from any assessment in the
primary studies (for example, those who never returned
for assessment after randomisation), they were considered
non-responders both in the combination group and mon-
otherapy group. Relative risks (RR) and their 95% confi-
dence intervals were calculated using random effects
model rather than a fixed effects model because of its gen-
eralizability [37].
For continuous outcomes, the standardized weighted
mean difference (SMD) was calculated for end-point data
of completers only using random effects model.
Heterogeneity, which refers to variability among studies
in a systematic review and generally derives from clinical,
methodological or statistical diversity [35], was assessed
by Chi-square statistics and I-square statistics [38]. When
substantive heterogeneity was found (p < 0.10 or I-
squared > 30%), sources were investigated.
We also planned sub-group analyses in terms of types of
psychotherapy, and sensitivity analyses to examine
robustness of the review's findings, by a) limiting to trials
with patients who had no comorbid physical or mental
disorders, b) excluding trials with no regular concomitant
use of an antidepressant, c) limiting to trials where the
psychotherapy used had high adequacy, and d) limiting
to trials where both allocation concealment and assessor
blindness were noted.
Results
Description of studies
The electronic search identified 12 studies from
CCDANCTR-Studies, 123 from CCDANCTR-References
and 67 from CENTRAL. Browsing their titles and
abstracts, 60 articles were identified by either of the two
independent reviewers as possible candidates and their
full copies were obtained. Ten studies were then selected
to proceed to strict eligibility check stage. During further
reference search, SciSearch and personal contacts, one
additional study possibly eligible was identified. Two
independent reviewers examined the strict eligibility of
these 11 studies and 4 studies remained. The inter-rater
reliability of the items of strict eligibility criteria was per-
centage agreement of 96% and kappa of 0.71 (95%CI:
0.37 to 1.0). Discrepancies were resolved by consensus.
Two of the studies were finally excluded because benzodi-
azepine was given only on the day of the visit [39] or
because only the number of completers in both interven-BMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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tion and control groups were described [40] (Table 1),
and we arrived at two studies [20,41] (Table 2).
Marks and his colleagues provided two comparisons,
which comprised of one comparison between combina-
tion therapy and psychotherapy alone and the other
between combination and benzodiazepine alone
[20,34,42-52]. Wardle and her colleagues provided a
comparison between combination therapy and psycho-
therapy alone [41,53]. We therefore obtained data for a
total of 243 participants from two studies (Table 3).
Regarding diagnostic criteria, the former study included
patients who had panic disorder with agoraphobia, and
the latter included patients with agoraphobia. Though the
latter did not mention panic disorder in diagnostic inclu-
sion criteria, contact with the authors revealed that all
patients in the study had some panic attacks and almost
all of the patients would be qualified as panic disorder
with agoraphobia according to DSM-IV.
The former employed alprazolam as a benzodiazepine
and exposure as psychotherapy; the latter did diazepam as
a benzodiazepine and exposure as psychotherapy. The
duration of interventions was 16 weeks in both studies,
which included drug withdrawal (Table 2).
With regard to outcomes, means and standard errors (SEs)
of clinical global rating were reported at all the time
points of assessment in one study [49]. SDs were calcu-
lated from SEs and the numbers of responders ("very
much or "much" improved on Clinician's Global
Improvement) were imputed. The other study assessed
clinical global rating only at the 12-months follow-up
assessment [41], so we defined responders as patients
with 50% reduction from baseline on the mobility when
alone subscale (MAL) of the Mobility Inventory [54]. No
study reported on patients' satisfaction and economic
costs. The numbers of patients who dropped out due to
side effects or suffered from withdrawal symptoms upon
cessation of treatment were not specified either. No infor-
mation is given about relapse rates during follow-up in
both of the studies. Additional treatment (taking benzodi-
azepines after the treatment period) is reported in one
study [41], but the number of participants in each of the
intervention and the control arms is not given.
With regard to study quality, neither study described con-
cealment of allocation but both reported having kept
assessors blind. The inter-rater reliability of these two
validity criteria was 100% agreement for both. Regarding
adequacy of the psychotherapies provided, one study was
rated high [20], and the other moderate [41].
Psychotherapy plus Benzodiazepine versus Psychotherapy
Acute phase treatment
Two comparisons from two studies were included
between combined psychotherapy and benzodiazepine
versus psychotherapy alone in the acute phase treatment
(Table 3). The data suggested the relative risk (RR) for
response for the combination was 1.25 (95% CI: 0.78 to
2.03; P = 0.35) at 2 months during the acute phase treat-
ment (Figure 1). No heterogeneity was observed (χ2 =
0.00, df = 1, P = 0.95; I2 = 0.0%).
With regard to secondary outcomes, although combina-
tion therapy was not shown to have significant superiority
to psychotherapy alone in terms of global severity of panic
disorder (Figure 2), the combination therapy was superior
in panic frequency and social functioning (panic fre-
quency: SMD 0.38; 95%CI 0.02 to 0.72; P = 0.04, social
functioning: SMD 0.51; 95%CI 0.01 to 1.01; P = 0.05).
Both combination therapy and psychotherapy alone
groups had similar dropout rates (RR = 0.81, 95% CI: 0.47
to 1.38; P = 0.44).
After the end of acute treatment
Little difference between combination therapy and psy-
chotherapy alone groups was shown on the whole (RR =
Table 1: Reasons for excluding studies
Study Reason for exclusion
Chambless et al. 1982 [59] The combination arm used barbiturates, not benzodiazepines.
Chouinard et al. 1982 [60] Some participants had combination therapy but their outcomes were not reported.
Craske 1991 [61] The interventions did not involve psychotherapy combined with benzodiazepine.
Echeburua et al. 1993 [62] Participants were diagnosed as agoraphobia but had no panic attack.
Hafner and Marks 1976 [39] Participants did not take benzodiazepine on regular basis but on the day of visit only.
Johnston and Gath 1973 [63] Participants did not take benzodiazepine on regular basis but on the day of flooding only.
Lopez-Alonso and Gomze-Jarabo 2000 [40] Only the number of completers in both intervention and control groups were described.
Otto et al. 1993 [64] All participants were prescribed benzodiazepine and this was then tapered.
Riley et al. 1995 [65] The interventions did not involve the combination of psychotherapy and benzodiazepine.
Spiegel et al. 1994 [66] All participants were prescribed benzodiazepine and this was then tapered.
Whitehead et al. 1978 [67] All participants had animal phobia, not panic disorder.B
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Table 2: Characteristics of the included studies
Study Participants Acute phase 
interventions
Maintenance
interventions
Follow-up Definition of response Other outcomes
Marks 1993 [20] Diagnosis: DSM-III PD with 
AG
Mean duration: 8 years
Mean age: 35 years
81% female
Psychiatric comorbidity: 
10% current MDD, 30% past 
MDD, 10% social phobia, 
25% specific phobia
Physical comorbidity: 
unspecified
Duration: 16 weeks
Weeks 0–8: benzodiazepine 
(alprazolam [A]) or pill-
placebo (P), with live 
exposure (E) or with 
relaxation (R) (R = 
psychological-placebo).
Weeks 9–16: A & P tapered 
to zero, no E or R given.
i.e. 4 groups: AR, AE, PR, PE
AR=bz alone
AE=bz+psychotherapy
PR=double placebo
PE=psychotherapy alone
1. Benzodiazepine mean dose 
5.8 mg/day)
2. Psychotherapy or placebo 
= 2 hours live exposure or 
relaxation 6 sessions
None Assessments "at the end of 
acute treatment" gathered at 
2 weeks after actual 
treatment termination. Long-
term follow-up at 7 months 
after treatment termination.
'Very much' or 'much' 
improved on Clinician's CGI. 
Numbers of responders 
calculated using normal curve 
[36]
Global severity of PD: 7-
point CGI rated by assessors
Panic attack: total number 
of major panics per week
Agoraphobia: 4 phobic 
targets avoidance
General anxiety: 14-item 
HAM-A
Depression: 17-item HAM-
D Social functioning: 9-point 
assessor-rated scale for 
work, social, and family 
adjustment
Wardle 1994 [41] Diagnosis: ICD-9 and DSM-
III-R AG
Mean duration: 11–12 
years
Mean age: 41–45 years in 
each arm
82% female
Psychiatric co morbidity: 
Not specified
Excluded if had comorbid 
heart disease, alcohol 
problems, drug abuse, 
pregnancy or anticipated 
pregnancy, or major 
psychotic illness
Duration: 16 weeks
16 weeks for benzodiazepine 
(with drug taper) and 8 
weeks for psychotherapy 
(week 4–12)
1. Diazepam (the dose was 
kept to 5 mg/day unless the 
patient requested an 
increase) + BT (eight 2-hour 
sessions over a 7 week 
period by a clinical 
psychologists). Medication 
was tapered to zero from 
week 13 to 16.
2. BT + placebo drug
None At 1, 6, 12 months after 
treatment discontinuation
Patients were advised to 
continue self-exposure. After 
the acute treatment phase, 
all patients were withdrawn 
during 0–1 month after 
treatment discontinuation. 
No further treatment was 
offered over the follow-up 
period unless the patient's 
clinical condition 
necessitated intervention.
50% reduction on MAL from 
the baseline by looking at the 
raw data
Global severity of panic 
disorder: MAL
Panic attack: Panic 
frequency in past week
Agoraphobia: MAL
General anxiety: STAIS-T
Depression: BDI
Social functioning: Not 
applicable
AG: agoraphobia; BDI: Beck Depression Inventory; BT: Behaviour therapy; CGI: Clinician's Global Improvement; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale; 
MAL: Mobility Inventory 'Mobility Alone'; MDD: Major depressive disorder; MAL: Mobility index – Mobility alone; PD: panic disorder; STAIS-T: State-Trait Anxiety Inventory-Trait AnxietyB
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Table 3: Results of meta-analyses
Psychotherapy+Benzodiazepine vs Psychotherapy alone Psychotherapy+Benzodiazepine vs Benzodiazepine alone
Statistical
method
Number of
comparisons
Number of
participants
Effect size
[95% CI]
Number of
comparisons
Number of
participants
Effect size
[95% CI]
Acute phase 
treatment (at 2–4 
months)
Response RR 2 166 1.25 [0.78, 2.03] 1 77 1.57 [0.83, 2.98]
Global severity SMD 2 122 0.15 [-0.21, 0.50] 1 68 0.63 [0.14, 1.11]
Frequency of panic 
attacks
SMD 2 124 0.38 [0.02,0.74] 1 68 0.18 [-0.29, 0.66]
Phobic avoidance SMD 2 122 0.09 [-0.27, 0.45] 1 68 1.17 [0.65, 1.68]
General anxiety SMD 1 60 0.08 [-0.43, 0.59] 0 0 Not estimable
Depression SMD 2 120 0.17 [-0.23, 0.58] 1 68 0.14 [-0.34, 0.62]
Social functioning SMD 1 64 0.51 [0.01, 1.01] 1 68 1.05 [0.54, 1.56]
Dropouts for any 
reason within 2–4 
months
RR 2 166 0.81 [0.47, 1.38] 1 77 1.85 [0.50, 6.87]
Dropouts due to side 
effects within 2–4 
months
RR 0 0 Not estimable 0 0 Not estimable
Immediately after 
the end of drug 
taper
Response RR 2 166 0.78 [0.45, 1.35] 1 77 3.39 [1.03, 11.21]
Global/Avoidance/
Panic
SMD 2 99 -0.31 [-0.71, 0.09] 1 53 0.75 [0.19, 1.31]
6–12 months after 
treatment 
termination
Response RR 2 166 0.62 [0.36, 1.07] 1 77 2.31 [0.79, 6.74]
Global/Avoidance/
Panic
SMD 2 95 -0.19 [-0.59, 0.22] 1 35 0.99 [0.28, 1.70]
CI: confidence interval; RR: relative risk; SMD: standardized weighted mean differenceBMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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0.78, 95% CI: 0.45 to 1.35; P = 0.37) (Figure 3). No het-
erogeneity was observed (χ2 = 0.05, df = 1, P = 0.82; I2 =
0.0%). In terms of the global severity, weak trend of infe-
riority of the combination therapy was observed (SMD -
0.31, -0.71 to 0.09, P = 0.12) (Figure 4).
Long-term after treatment termination
At either 12 [41] or 7 [20] months of naturalistic follow-
up after treatment termination, the RR of response rate
showed a trend in favour of psychotherapy alone over
combination (RR = 0.62, 95%CI: 0.36 to 1.07; P = 0.08)
(Figure 5). No heterogeneity was observed (χ2 = 0.01, df =
1, P = 0.93; I2 = 0.0%). In terms of the global severity, this
trend was not observed (SMD -0.19, -0.59 to 0.22, P =
0.37) (Figure 6).
Psychotherapy plus Benzodiazepine versus 
Benzodiazepine treatment
Acute phase treatment
Comparing combined psychotherapy plus benzodi-
azepine with benzodiazepine alone in one comparison
[20], the RR for response for the combination was 1.57
(95%CI: 0.83 to 2.98; P = 0.17) at 2 months during acute
phase treatment (Table 3), which was not statistically sig-
nificant.
The significant superiority of the combination therapy
was observed for some secondary outcomes including glo-
bal severity of the disorder (SMD 0.63; 95%CI 0.14 to
1.11), phobic avoidance (SMD 1.17; 0.65 to 1.68) and
social functioning (SMD 1.80; 0.99 to 2.61). There was no
Psychotherapy plus benzodiazepine vs. psychotherapy alone: global severity at 2–4 months during acute phase treatment Figure 2
Psychotherapy plus benzodiazepine vs. psychotherapy alone: global severity at 2–4 months during acute phase 
treatment. Standardised mean difference was calculated using both CGI [20] and Mobility Alone [41].
Study  PT+Benz
or sub-category N Mean
o  PT  SMD (random) Weight  SMD (random)
 (SD) N Mean (SD)  95% CI %  95% CI
Exposure therapy
Marks 1993    34  2.00(0.60)   30 2.20(1.10) 52.23  0.23 [-0.27, 0.72]
41)   28    82.39(25.51) 47.77  0.06 [-0.46, 0.57]
  58
Wardle 1994    30 80.87(27.
Total (95% CI )    64 100.00  0.15 [-0.21, 0.50]
=0 % Test for heterogeneity: Chi² = 0.22, df = 1 ( P = 0.64), I²
Test for overall e ffect: Z = 0.80 ( P = 0.42 )
1  0.5 0  -0.5 -1
 Favours PT+Benzo  Favours PT
Psychotherapy plus benzodiazepine vs. psychotherapy alone: response at 2–4 months during acute phase treatment Figure 1
Psychotherapy plus benzodiazepine vs. psychotherapy alone: response at 2–4 months during acute phase 
treatment. Relative risk of response was calculated using both CGI [20] and Mobility Alone [41].
Study  PT+Benzo
or sub-category  n/N
 PT  RR (random) Weight  RR (random)
 n/N  95% CI %  95% CI
Exposure therapy
 Marks 1993   17/40  13/38 71.18 1.24 [0.70, 2.20]
7/44  28.82 1.29 [0.53, 3.15]
82
Wardle 1994 9/44
Total (95% CI ) 84 100.00 1.25 [0.78, 2.03]
0%
Total events: 26 (PT+Benzo), 20 (PT )
Test for heterogeneity: Chi² = 0.00, df = 1 ( P = 0.95), I² = 
Test for overall e ffect: Z = 0.93 ( P = 0.35 )
 10 5 2 1 0.5 0.2  0.1
 Favours PT  Favours PT+BenzoBMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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significant difference between both arms in frequency of
panic attacks and depression.
No difference was observed in the overall dropouts either.
After the end of acute phase treatment
Superiority of combination to benzodiazepine alone was
observed both in the response rate (RR = 3.39, 95% CI:
1.03 to 11.21, P = 0.05) and the global severity (SMD =
0.75, 95% CI: 0.19 to 1.31, P = 0.009).
Long-term after treatment cessation
In terms of response after 7 months after treatment cessa-
tion, a weak trend in favour of the combination therapy
(RR = 2.31, 95% CI: 0.79 to 6.74, P = 0.12) in terms of
response rates, and a statistically significant superiority of
the combination in terms of global severity was observed.
Subgroup and sensitivity analyses
Due to the limited number of comparisons available, it
was not possible to undertake any subgroup analyses or
sensitivity analyses.
Discussion
Despite extensive literature searches and personal com-
munication, only two rigorous studies were identified that
examined combined benzodiazepines and psychotherapy
for panic disorder.
Psychotherapy plus benzodiazepine vs. psychotherapy alone: global severity after the end of acute treatment Figure 4
Psychotherapy plus benzodiazepine vs. psychotherapy alone: global severity after the end of acute treatment. 
Standardised mean difference was calculated using both CGI [20] and Mobility Alone [41].
Study  PT+Benzo
or sub-category N Mean (SD)
 PT  SMD (random) Weight  SMD (random)
N Mean (SD)  95% CI %  95% CI
Exposure therapy
Marks 1993 28  2.30(1.10) 24  1.80(1.00) 51.74   -0.47 [-1.02, 0.09]
 23   77.43(29.42) Wardle 1994  24   81.46(23.99) 48.26   -0.15 [-0.72, 0.42]
 47 100.00   -0.31 [-0.71, 0.09] Total (95% CI )  52
Test for heterogeneity: Chi² = 0.62, df = 1 ( P = 0.43), I² = 0 %
Test for overall e ffect: Z = 1.54 ( P = 0.12 )
1  0.5 0  -0.5 -1
 Favours PT+Benzo  Favours PT
Psychotherapy plus benzodiazepine vs. psychotherapy alone: response after the end of acute treatment Figure 3
Psychotherapy plus benzodiazepine vs. psychotherapy alone: response after the end of acute treatment. Rela-
tive risk of response was calculated using both CGI [20] and Mobility Alone [41].
Study  PT+Benzo
or sub-category  n/N
 PT  RR (random) Weight  RR (random)
 n/N  95% CI %  95% CI
Exposure therapy
 Marks 1993 11/40     14/38 70.40  0.75 [0.39, 1.43]
7/44 Wardle 1994  6/44 29.60  0.86 [0.31, 2.35]
   82 100.00  0.78 [0.45, 1.35] Total (95% CI) 84
Total events: 17 (PT+Benzo), 21 (PT )
Test for heterogeneity: Chi² = 0.05, df = 1 ( P = 0.82), I² = 0%
Test for overall effect: Z = 0.90 (P = 0.37)
 10 5 2 1 0.5 0.2  0.1
 Favours PT  Favours PT+BenzoBMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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What little evidence there is suggests, however, that
behaviour therapy (exposure) plus benzodiazepines may
be superior to benzodiazepines alone, especially at the
end of acute treatment (RR = 3.39, 1.03 to 11.21), and
possibly also during the acute phase and at long-term fol-
low-up. The combined therapy may also be superior to
behaviour therapy alone during the acute phase, but this
possible superiority may not persist and perhaps invert
during the follow-up 6–12 months after treatment termi-
nation.
With respect to combination therapy versus benzodi-
azepines alone, secondary endpoints representing contin-
uous measures also hint at the superiority of the
combination during the acute phase treatment, in that the
combination was significantly superior to benzodi-
azepines in terms of the global severity, phobic avoidance,
and social functioning. Over the long term, this superior-
ity was not statistically significant (RR = 2.31, 0.79 to
6.74). However, the secondary outcome demonstrated
combination therapy was significantly superior to benzo-
diazepine alone. In addition, data from one of the
included RCTs indicated that even placebo was not infe-
rior to behaviour therapy alone or benzodiazepine alone
for panic attacks as opposed to phobias and disability, for
which placebo was indeed inferior. [20].
With regard to behaviour therapy alone, some secondary
endpoints hinted at the superiority of the combination
during the acute phase treatment (frequency of panic
Psychotherapy plus benzodiazepine vs. psychotherapy alone: global severity at 6–12 months after treatment termination Figure 6
Psychotherapy plus benzodiazepine vs. psychotherapy alone: global severity at 6–12 months after treatment 
termination. Standardised mean difference was calculated using both CGI [20] and Mobility Alone [41].
Study  PT+Benzo
or sub-category N Mean (SD
 PT  SMD (random) Weight  SMD (random)
) N Mean (SD)  95% CI %  95% CI
Exposure therapy
Marks 1993     17  1.80(0.80)     23  1.60(1.00) 41.50   -0.21 [-0.84, 0.42]
)     27 77.48(29.80) 58.50   -0.17 [-0.70, 0.36]
    50
Wardle 1994     28 82.21(26.03
100.00   -0.19 [-0.59, 0.22] Total (95% CI )     45
Test for heterogeneity: Chi² = 0.01, df = 1 ( P = 0.91), I² = 0 %
Test for overall e ffect: Z = 0.90 ( P = 0.37 )
1  0.5 0  -0.5 -1
 Favours PT+Benzo  Favours PT
Psychotherapy plus benzodiazepine vs. psychotherapy alone: response at 6–12 months after treatment termination Figure 5
Psychotherapy plus benzodiazepine vs. psychotherapy alone: response at 6–12 months after treatment termi-
nation. Relative risk of response was calculated using both CGI [20] and Mobility Alone [41].
Study  PT+Benzo
or sub-category  n/N
 PT  RR (random) Weight  RR (random)
 n/N  95% CI %  95% CI
Exposure therapy
 Marks 1993   10/40   15/38  65.73   0.63 [0.33, 1.23]
0/44  34.27   0.60 [0.24, 1.51]
   82
Wardle 1994    6/44   1
100.00   0.62 [0.36, 1.07] Total (95% CI ) 84
Total events: 16 (PT+Benzo), 25 (PT )
Test for heterogeneity: Chi² = 0.01, df = 1 ( P = 0.93), I² = 0 %
Test for overall e ffect: Z = 1.73 ( P = 0.08 )
 10 5 2 1 0.5 0.2  0.1
 Favours PT  Favours PT+BenzoBMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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attack, social functioning). Some authors have argued that
the combination therapy is superior to psychotherapy
alone in the long term [28,31]. However the results in the
present review failed to reach statistical significance in
terms of response rate (RR = 0.62, 0.36 to 1.07, P = 0.08)
or the secondary outcome representing global severity of
panic attacks (SMD = -0.19, -0.59 to 0.22, P = 0.37).
Considering these results, benzodiazepine alone is not to
be recommended for those who have access to appropri-
ate resources of behaviour therapy.
We did not focus on the combined antidepressants and
psychotherapy in the present review, but our companion
systematic review on this topic also concluded that either
combined therapy or psychotherapy alone rather than
antidepressants alone might be chosen as first-line treat-
ment for panic disorder with or without agoraphobia [6].
Combining the conclusions of the two reviews, pharma-
cotherapy alone, be it by an antidepressant or by a benzo-
diazepine, may be avoided in treatment for panic disorder
where psychotherapy is available.
One has to note some possible weaknesses in the present
review. First of all, only two studies including 243 patients
diagnosed as panic disorder with agoraphobia were iden-
tified, type II errors were therefore likely and even the sig-
nificant results might have limited generalizability.
Moreover, we were not able to do any analysis on panic
disorder without agoraphobia and managed only to
establish very limited evidence for panic disorder with
agoraphobia. Secondly, generalizability of the present
findings beyond specialist psychiatric settings is not
straightforward. The included studies were conducted at
psychiatric hospitals under psychiatrists' and clinical psy-
chologists' administration [20,41], so that generalizability
of the results of the present review to primary care may be
questioned. Another concern on generalizability of the
review may arise from the fact that participants were lim-
ited to those having been able to tolerate being off medi-
cation before entering the study in one study [20]. In
addition, regarding use of benzodiazepines, one included
study employed a huge daily dose of alprazolam in both
the benzodiazepine arms [20] compared to the dose usu-
ally recommended in clinical practice, and this could have
had negative effects on these arms. The other included
study [41] used diazepam as benzodiazepine in relatively
lower dose compared to previous studies which involved
diazepam as treatment for panic disorder [55-58].
Although diazepam has been demonstrated not only
superior to pill-placebo but also equally effective com-
pared with alprazolam [56,58], this issue could have
diminished efficacy of diazepam and have diluted differ-
ences between combined therapy and psychotherapy
alone. Thirdly, the definition of "response" employed in
the present study differs from study to study, due to
reported outcomes in the original reports. Clinical global
rating was employed in one study [20] and phobic avoid-
ance scale in the other [41]. The proportions of respond-
ers are much smaller in one study [41] than the other [20],
possibly due to different definitions of response.
Although no significant heterogeneity has been observed
through the analyses in the present review, one might
think these definitions are arbitrary or plausible. How-
ever, we failed to obtain clinical global scale in the latter
[41] in spite of contacting the original authors. We there-
fore utilized only phobic avoidance scale to define the
response, since this has been shown to better represent the
patients' global status [34]. Last but not least, all the
included studies dealt with psychotherapy in the form of
exposure therapy. Other forms of psychotherapies includ-
ing cognitive restructuring and psychodynamic therapy
also need to be examined in combination with benzodi-
azepines.
On the other hand, the present review may have several
strengths. First, we performed a systematic and compre-
hensive search for the relevant trials. All references to pos-
sible candidate studies were investigated to identify
relevant ones. The authors of the included studies were
contacted to give more information about their studies
and other possibly relevant ones. Consequently, our anal-
yses managed to include some unpublished data (MAL)
in one study [41]. Second, though there are many narra-
tive reviews on efficacy of combination therapy against
either monotherapy that included both high-quality and
low-quality studies all together, we limited our systematic
review only to high quality RCTs. These RCTs were also
conducted while keeping assessors blind. Our approach
minimized bias and therefore offered more rigorous evi-
dence. Third, we applied strict ITT principle, by means of
imputing response rates from continuous measures of
global severity for panic disorder and counting all the
dropouts as non-responders, as we were interested in the
fate of all patients who began the acute phase after ran-
domisation, not just those who completed it. Counting
dropouts as non-responders might appear too stringent as
some dropouts may have improved, but we cannot con-
firm their percentage. Given this circumstance, this
approach is the most conservative estimate of the
response rate, and in the absence of any stronger and
more rational alternative, we decided to remain conserva-
tive with regard to either treatment arm.
Conclusion
In conclusion, we would like to make some recommenda-
tions both for clinicians and for researchers as follows.BMC Psychiatry 2007, 7:18 http://www.biomedcentral.com/1471-244X/7/18
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Implications for practice
Currently, there is inadequate evidence to assess the clini-
cal effects of combined benzodiazepine and psychother-
apy treatment for patients who are diagnosed as panic
disorder with agoraphobia, and no rigorous RCT exists for
panic disorder without agoraphobia or for psychotherapy
other than exposure therapy. Based on this limited evi-
dence, exposure therapy may be recommended for
patients with agoraphobia who have access to appropriate
resources. Benzodiazepine alone is not to be recom-
mended for those in such a situation. It seems possible
that combined therapy is superior to exposure therapy
alone in the acute treatment, but after the acute treatment
is terminated, this trend may be reversed.
Implications for research
More high-quality trials for combined benzodiazepine
and psychotherapy treatment must be conducted before
making any stronger treatment recommendation.
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